Further analysis of clinical data revealed that low expression of RORα and high expression of ECM1 and VEGFR2 were all associated with poor overall survival (OS) and progression-free survival (PFS) in patients with PARP inhibitor-resistant ovarian cancer. Here, ECM1 is linked to ovarian cancer.